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Calcium blockade versus ACE inhibition in clipped and unclipped
kidneys of 2K-iC rats. ACE inhibitors have been shown to worsen the
kidney damage occurring distal to a renal artery stenosis. To determine if
this effect was due to the decrease of arterial pressure or to an inhibition
of the formation of angiotensin, we compared the effects of equihypoten-
sive doses of an angiotensin converting enzyme inhibitor (enalapril) and a
long-acting calcium antagonist (Ro 40-5967) in 2K-iC rats. The rats were
treated for five weeks with either enalapril, Ro 40-5967, or were left
untreated. A group of sham operated rats was used as control. At the end
of the five-week treatment period, proteinuria, plasma urea and creatinine
were measured and quantitative morphometry of the clipped and un-
clipped kidneys was performed. Ro 40-5967, despite an absence of
inhibition of the renin-angiotensin system, worsened the lesions of the
clipped kidney to the same extent as enalapril. In contrast, the effects of
both drugs on the unclipped kidney were different. Ro 40-5967, and not
enalapril, increased the weight and the glomerular surface area of the
unclipped kidney. Ro 40-5967 did not change the glomeruloscierosis
index, which was improved by enalapril. In contrast with enalapril, Ro
40-5967 decreased plasma urea and creatinine concentrations. Only
enalapril decreased proteinuria which originated from the unclipped
kidney as shown by nephrectomy experiments. We conclude that during
ACE inhibition the fall in renal perfusion pressure seems to be the main
determinant of the renal damage distal to a renal artery stenosis,
independently of a blockade of the renin-angiotensin system. However,
pharmacological effects other than the decrease of arterial pressure play
an important role in the unclipped kidney.
Blockade of the renin-angiotensin system (RAS) by angiotensin
converting enzyme (ACE) inhibition appears to be a logical
therapeutic approach in patients with a unilateral renal artery
stenosis. It is extremely effective in lowering blood pressure.
However, it can worsen the function of the stenotic kidney of
these patients [1, 2]. Similarly, in a rat model of unilateral renal
artery stenosis (2K-iC), ACE inhibition worsens histological
lesions of the stenotic kidney resulting in a pharmacological
nephrectomy [3—5]. This adverse effect on the stenotic kidney has
been attributed to the interruption of the intrarenal RAS which
might be responsible for the maintenance of the glomerular
filtration rate in presence of a decreased renal perfusion pressure
due to renal stenosis [6, 71. Other antihypertensive drugs such as
nifedipine [8, 9] and sodium nitroprussate [10], which decrease
blood pressure without interrupting the RAS, seem to have less
deleterious effects on the stenotic kidney. However, these drugs
are also less effective in decreasing arterial pressure than ACE
inhibitors. Therefore, it is still not known whether the drop of
arterial pressure or the local inhibition of the RAS causes the
morphological changes of the clipped kidney.
Unilateral renal artery stenosis creates a state where, in the
same animal, the two kidneys have opposite changes in their
endocrine and excretory function [11—13]. The clipped kidney is
protected from high perfusion pressure, secretes renin in excess
and has an impaired sodium excretion, whereas the unclipped
kidney, exposed to a high perfusion pressure, stops synthesizing
and secreting renin and eliminates sodium.
Ro 40-5967 is a new non-dihydropyridine calcium antagonist
which has been shown to induce a marked and long lasting
reduction of blood pressure in 2K-iC rats [14]. Using this drug it
was possible to compare the effects of ACE inhibition and calcium
antagonist on the clipped and unclipped kidneys, for a similar
decrease of arterial pressure, and thus to evaluate the role of
arterial pressure reduction in the morphological and functional
changes induced by ACE inhibition.
Methods
General
Eight-week-old male normotensive Wistar rats (FUllinsdorf,
Switzerland) were used. Under barbiturate anesthesia (sodium
hexobarbital, Bayer, Frankfurt, Germany), the left renal artery
was stenosed with a silver clip (slit width 0.2 mm) and the right
renal artery was left intact. Sham-operated rats were used as
controls (N = 14). Six weeks after surgery, the systolic blood
pressure (SBP) of the 2K-iC rats was measured indirectly using
the tail cuff method. SBP was measured once a week for two
weeks, and all 2K-iC rats with SBP greater than 170 mm Hg were
included in the study. This limit of 170 mm Hg was chosen on a
statistical basis in order to avoid overlap with the normotensive
group. Eighty-four from the 175 operated rats met this criterion.
Selection of equihypotensive doses of Ro 40-5967 and enalapril
In three 2K-iC hypertensive rats (with a SBP according to the
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above criterion), not included in the rest of the study, telemetry
was used [15] to verify that the decrease in arterial blood pressure
induced by either enalapril (30 mg/kg/day) or Ro 40-5967 (30
mg/kg/day) was similar. After recovery from telemetry implanta-
tion surgery, each rat was exposed to each drug for seven days in
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a crossover design, with a washout period of seven days between
the two acute treatment periods. The falls in blood pressure
induced by the two drugs were similar in extent and duration (Fig.
1).
Study design
Two sets of experiments were performed.
In the first study, 48 rats (selected from 75 operated rats) were
randomly divided into three groups of 16 rats. After baseline
plasma renin concentration (PRC) determinations, these rats
were either left untreated or were treated with enalapril or Ro
40-5967 for five weeks. SBP of each rat was measured once a week
at the end of the morning. On the last day of the five-week
treatment period, under ether anesthesia blood was obtained
from the retro-orbital vein for plasma urea, creatinine and renin
determinations. Then the rats were sacrificed and both kidneys
removed, weighed and prepared for biochemical and morphomet-
nc analyses as described below. A group of 14 normotensive
sham-operated rats, subjected to the same protocol served as
controls.
In a second complementary study (study 2) with the same
protocol, we specifically evaluated proteinuria and its origin
(clipped or unclipped kidneys). For this purpose, the rats followed
the same protocol as in the first study, but at the end of the
treatment period proteinuria, plasma urea and creatinine were
measured before and 48 hours after nephrectomy of the clipped
kidney. Qualitative morphometry was also performed in these rats
in order to confirm the findings of the first study.
Measurement of biochemical variables
Plasma urea and creatinine concentrations were measured by
an autoanalyzer (Kontron, Zurich, Switzerland).
Proteinuria was measured by an autoanalyzer (Kontron). The
rats were placed in individual metabolic cages (Ebeco, Castro-
pranzel, Germany), and 24-hour urine collections were performed
for proteinuria determination.
Fig. 1. Actual recording of the arterial
blood pressure measured in one 2K-iC
rat instrumented with a telemetric
system. The top trace corresponds to
systolic, intermediate trace to mean
and bottom trace to diastolic blood
pressure. Three rats were treated for
seven days either by Ro 40-5967 (30
mg/kg/day) or enalapril (3 mg/kg/day)
according to a crossover design and
were followed with telemetry.
Plasma renin concentration (PRC) was measured by radioim-
munoassay (RIA) of the angiotensin I generated by the incubation
of plasma with an excess of angiotensinogen provided in renin-
free plasma from rats binephrectomized 24 hours previously [16].
To measure renal renin content, each kidney (clipped and
non-clipped) was cut through its longitudinal axis and one-half
was frozen. After thawing, renin was extracted as previously
described [171. Tissue renin activity was measured by RIA of the
angiotensin I generated by incubation with an excess of rat renin
substrate. Protein measurements were made according to Lowry's
method.
Renal pathology and morphometty by light microscopy
The half of each kidney not used for biochemical measurements
was fixed by immersion in 4% paraformaldehyde and embedded
in paraffin for the qualitative and quantitative morphological
analyses.
Qualitative and semiquantitative analyses. Two independent
investigators blinded as to the experimental group performed the
analysis. Four-gm-thick sections were stained with Masson's
trichrome. The presence of infarction, glomerular, tubulointersti-
tial and vascular lesions was assessed in each kidney. Each type of
lesion was graded semiquantitatively using the methods of Raij,
Azar and Keane [181 and Olson, Wilson and Heptinstall [19].
The presence of glomerulosclerosis, and tubulointerstitial and
vascular lesions was evaluated in non-clipped kidneys. For assess-
ing glomerulosclerosis, 50 superficial and 50 juxtamedullary gb-
meruli in each kidney were observed at X400 magnification and
graded (0 to 4) according to the degree of injury present. Grade
of 0 denoted a normal glomerulus. Slight glomerular damage
(grade 1) included abnormalities such as a mild increase in
mesangial sclerosis and/or hyalinosis with focal adhesions, involv-
ing less than 25% of the glomerulus; grade 4 represented sclerosis
of 75 to 100% of the glomerulus. A glomerular damage index was
calculated for the 100 glomeruli and corresponded to the sum of
grades assigned to all glomeruli.
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Fig. 2. Sequential automated morphometric analysis of the different glomendar domains. A. grey level digitalized and threshold image of a glomerulus(x250). B. the whole glomerular surface defined by the internal edge of Bowman's capsule. C. the whole surface area of the glomerular tuft. ft.
extracellular matrices, in green, comprise mesangial domain and capillary walls.
Every third field of each kidney (total of 10 fields/kidney) was
assessed at X 100 magnification for tubulointerstitial lesions (in-
terstitial inflammation and fibrosis, tubular atrophy and casts) and
assigned an injury grade (0 to 3). Grade 0 represented normality,
grade 1 denoted lesions involving less than 25%, grade 2 lesions
involved between 25 and 50%, and grade 3 lesions involved more
than 50% of the field. The score corresponding to tubulointersti-
tial lesions was obtained for each kidney by summing the grades
given to each field, as above.
Vascular lesions in each kidney were attributed grades of
severity from 0 to 4 in 10 fields at X200 magnification. This grade
was based on both the severity of vascular wall thickening and the
extent of fibrinoid necrosis in afferent arterioles, interlobular
arterioles and small arteries. Grade 0 denoted a normal vessel;
grade 1 a mild vascular wall thickening; grade 2 a moderate
thickening; grade 3 a severe thickening (onion skin pattern); and
grade 4, fibrinoid necrosis. The vascular lesion score was obtained
using the same procedure as described above.
In clipped kidneys, the presence or absence of infarction was
assessed in 10 fields and tubulointerstitial lesions graded accord-
ing to the above criteria.
Quantitative morphometric analyses. One standardized section
through the longitudinal axis of each kidney was stained using the
red sirius technique [20]. Cortical and medullary surface areas and
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Table 1. Body weight, systolic blood pressure and biochemical variables of the 2K-iC rats in the two studies
First study Second study
Body SBP Creatinine Urea Body SBP Creatinine Urea
Group Treatment N weight g mm Hg pinol/liter mmol/liter N weight g mm Hg i.zmollliter mmol/liter
Sham-op Untreated 14 341 12 142 2 58.6 2.0 6.4 0.3 12 362 7 147 3 54.7 1.3 5.7 0.1
2K-iC Untreated 16 318 11 216 1? 68.9 3.2a 10.1 0.8a 12 316 2 219 15 64.8 3•9a 8.8 1.6
2K-iC
2K-iC
Enalapril
Ro 40-5967
16
15
313 7
315 9
158 8"
160 2b
65.6 2.2
61.7 26b
8.9 0.679 3ab 1212 343 9312 12 182 14b170 7" 59.3 1.258.9 1.0 7.5 0.36.9 0.2
Body weight and biochemical measurements were measured at the end of treatment. Systolic blood pressure (SBP) corresponds to the mean of 5
measurements performed once a week during the 5 weeks of treatment.
aP < 0.05 vs. sham-operatedbP < 0.05 vs. untreated
glomerular and tubular dimensions were determined. All vari-
ables were quantified by morphometty using a video camera
(Sony, Tokyo, Japan) connected to an image analysis processor
(Nachet 15000, Nachet, Evry, France) piloted by a microcomputer
(Macintosh II, Apple, Cupertino, California, USA). Three algo-
rithms in C language (using specific mathematic treatments such
as erosion, dilation and reconstruction) allowed sequencing of all
image analysis steps for each field.
Cortical and medullary surface areas in clipped and non-clipped
kidneys were determined by a simple threshold using a mono-
zoom macroscope (Nachet 15,000, Nachet; at a final calibration of
25 mIpixel). The corticomedullary border was traced manually in
each case.
Glomerular and tubular dimensions were determined in the
non-clipped kidneys. Quantitative analysis was not possible in the
clipped kidneys due to the variable tubular and glomerular
damage. Glomerular dimensions were measured using a light
microscope (X40 objective, 0.29 j.m/pixel) and all cortical gb-
meruli sectioned through a non-necrotic vascular pole were
analyzed. Each glomerulus measured was placed in the center of
the field and a black top hat technique allowed extraction of all
deeply stained structures (Fig. 2). The Bowman's capsule limits
were interactively corrected (if necessary) with a video pen. The
internal edge of the Bowman's capsule was taken to be the limit of
the entire glomerular surface. Total glomerular, glomerular tuft
and extracellular matrix surface areas and Bowman's capsule
mean thickness were automatically quantified by the analyzer.
The peripheral urinary surface area was obtained by subtracting
the glomerular tuft surface area from that of the total glomerulus.
In a preliminary study, we determined that the minimum number
of glomeruli required to obtain a convergent estimation of the
different variables was 30 for each kidney. Therefore, a total of
1860 glomeruli were quantified in the four groups of rats.
The following tubule dimensions were measured in the cortex,
exclusively in fields where tubules were sectioned transversely
(x25 objective, 0.51 sm/pixel): luminal and epithelial surface
areas, epithelial thickness and mean number of nuclei per tubule
section. Tubule limits were determined automatically and cor-
rected manually with a video pen if necessary. Tubules cut
non-transversely, as determined by a form factor less than 0.7,
were excluded [the form factor, equal to 4rX area / (perimeter)2,
had a value of 1 for a perfect circle and decreased with deforma-
tioni. The minimal number of fields required to obtain a conver-
gent estimations of the different tubular dimensions was 20
(representing a mean of 140 tubules per kidney and a total of 8680
tubules in the 4 groups).
Statistical analysis
All results are expressed as mean SEM. Differences between
groups were evaluated using a one-way ANOVA test followed by
a Fischer test for group comparisons. Cpmparisons between the
two treated groups were performed using a Student's (-test. The
incidences of renal lesions were compared using a 2test.
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Fig. 3. Distribution of proteinuria obtained from the 24-hour collection in
the 4 groups of rats (study 2) before (A) and after nephrectomy (B).
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Table 2. Plasma and renal renin concentrations (study 1)
Plasma renin concentration Renal renin concentration
ng Ang I/mi/hr pg Ang I/mg protein/hr
Group Treatment Week 0 Week 5 Clipped kidney Non-clipped kidney
Sham-op Untreated 41 6 12 1 5.42 1.00 5.31 3.86
2K-iC Untreated 35 8 62 26 14.74 2.31 1.80 Q57a
2K-iC Enalapril 49 20 79 12k' 36.51 14.98a 5•74 l.53b
2K-iC Ro 40-5967 46 16 45 12 12.80 2.49 3.28 1.03
Plasma renin concentration was measured at week 0 (before starting treatment) and after five weeks of treatment (week 5).
a P < 0.05 vs. sham-op
h P < 0.05 vs. untreated
CP < 0.05 vs. enalapril
Table 3. Kidney weight, cortical and medullary surface areas of the clipped and unclipped kidneys (study 1)
Clipped kidney Non-clipped kidney
Kidney Cortical Medullary Kidney Cortical Medullary
weight surface area surface area weight surface area surface area
Group Treatment g mm2 mm2 g mm2 mm2
Sham-op Untreated 0.88 0.07 27.9 2.6 40.0 3.2 1.02 0.03 24.6 1.1 40.1 3.1
2K-iC Untreated 0.63 0.07a 20.9 2.P 28.4 4.2a 1.17 0.04 28.9 1.3 43.9 1.7
2K-iC Enalapril 0.31 0.08 16.3 2.3a 15.8 48ab 1.24 0.05 28.5 1.9 44.0 3.6
2K-iC Ro 40-5967 0.39 007ab 18.2 2.8a 16.6 3.7' 1.43 O.O8 33.4 1.8 51.8 3.2a
a P < 0.05 vs. sham-operated
< 0.05 vs. untreated
°P < 0.05 vs. enalapril
Results
SBP and body weight in the four experimental groups
In the first study, at baseline before initiating treatment, the
three 2K-iC rat groups had similar levels of high blood pressure
(210 9, 211 9, 210 9 mm Hg in the untreated, enalapril and
Ro 40-5967 groups, respectively, Table 1). This result was con-
firmed in the second study (222 12, 221 12, 221 12 mm Hg
in the untreated, enalapril and Ro 40-5967 groups, respectively).
The blood pressures of the sham-operated rats were 145 1 and
145 3 mm Hg in the first and second studies, respectively. The
blood pressure distribution was the same in each hypertensive rat
group. The mean blood pressure, calculated from values obtained
during the five weeks of treatment, was decreased to the same
extent by both treatments (Table 1). In study 1, under treatment,
SBP was below 170 mm Hg in 10 of 16 rats in the enalapril group,
10 of 16 rats in the Ro 40-5967 group and 5 of 16 rats in the
untreated group. One of the Ro 40-5967 rats was excluded from
the first study due to unknown reasons; it was the only rat which
did not respond at all to this treatment. In this rat, Ro 40-5967
only reduced blood pressure during the first week: SBP was 145,
240, 235, 255 and 265 mm Hg for weeks 1 to 5, respectively.
Hypertensive rats had on average a lower body weight than
sham-operated rats. None of the drugs had a significant effect on
body weight.
Biochemical measurements
Plasma urea and creatinine concentrations. In the first study,
plasma urea was increased in all three groups of 2K-iC rats as
compared to sham-operated rats (Table 1). Only Ro 40-5967
decreased plasma urea significantly compared to untreated rats.
Plasma creatinine was increased in untreated rats compared to
sham-operated rats and was decreased only by Ro 40-5967 (P =
0.015).
Proteinuria. Eleven weeks after clipping and before nephrec-
tomy, proteinuria was different in the four groups (P = 0.024; Fig.
3). It was similarly increased in untreated and Ro 40-5967 treated
rats, (83.4 35 and 139 44 mg/24 hr, respectively), while
sham-operated rats and enalapril treated rats had lower values (28
5 and 26 23 mg/24 hr, respectively). Forty-eight hours after
nephrectomy, proteinuria remained significantly increased in the
Ro 40-5967 treated rats as compared to untreated hypertensive
and enalapril rats (78,0 23 vs. 22.5 3.5 and 23 2.2 mg/24 hr,
respectively, P = 0.008).
Plasma renin concentration. Six weeks after induction of hyper-
tension (before treatment), plasma renin concentration (PRC)
values of the three groups of 2K-iC hypertensive rats were not
significantly different from those of normotensive sham operated
rats (Table 2). At the end of the five week-treatment period, PRC
was higher in the 2K-iC untreated rats than in the sham-operated
rats. Three out of 16 untreated hypertensive rats had very high
PRC values (99, 284 and 356 ng/Ang I/ml/hr), severe vascular
lesions in the unclipped kidney and very high SBP (267, 282 and
284 mm Hg). Their evolution towards malignant hypertension
contributed to the increase of the mean PRC value of this group.
In the Ro 40-5967 group, PRC did not change under treatment,
while in the enalapril group, PRC increased significantly.
Renal renin content (RRC). The RRC of the clipped kidney was
approximately 8, 6 and 4 times higher than the RRC of the
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unclipped kidney in the untreated, enalapril and Ro 40-5967 rats,
respectively (Table 2). In comparison with untreated rats, enala-
pril increased the RRC of both the clipped and unclipped kidneys,
whereas Ro 40-5967 did not modify RRC.
Kidney weight
The weight of the clipped kidney of the untreated group was
decreased compared to the sham-operated group (Table 3). Both
anti-hypertensive treatments decreased the weight of the clipped
kidney to the same extent. The ratio of mean clipped kidney
weight/mean unclipped kidney weight in the untreated, enalapril
and Ro 40-5967 groups were 54, 25 and 31%, respectively. Ro
40-5967 treatment increased the weight of the non-clipped kidney
as compared to that found in untreated rats, whereas enalapril did
not.
Renal pathology (qualitative and semi-quantitative analysis)
No renal lesions were observed in sham-operated rats, whereas
lesions were observed in both kidneys of 2K-ic rats.
Clipped kidney. Renal artely stenosis induced two main types of
lesions: infarction and tubulointerstitial lesions including inflam-
mation, fibrosis, tubular atrophy and casts. Semi-quantitative
analysis clearly showed that the size of the infarcted area,
reflected by the infarction score, and the prevalence of the
Sham op Untreated Enalaprit Ro 40-5967
Sham op Untreated Enalapril Ro 40-5967
C
tubulointerstitial lesions, expressed by the tubulointerstitial lesion
score were similarly increased by both treatments in comparison
to untreated rats (Fig. 4). No vascular lesions were present in the
clipped kidneys even in untreated rats, This is probably due to the
presence of the clip which protected the kidney from the too high
peripheral blood pressure.
Non-clipped kidney. As expected, in addition to tubulointersti-
tial and glomerular lesions, hypertension induced vascular lesions
in the non-clipped kidney (Fig. 5), consisting of wall thickening in
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Fig. 4. Distribution of the kidney lesions score in the clipped kidney of the 4
groups of rats (studies I and 2). Open symbols represent individual rat
scores from the first study and filled symbols individual scores from the
second study.
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Table 4. Glomerular and tubular dimensions quantified by morphometry in the unclipped kidneys of the four experimental groups (study 1)
Group Treatment
Glomeruli Tubules
Glomerular
surface area
Extracellular
Glomerular matrix
tuft surface surface
area area
Peripheral
urinary
surface area
Thickness
of the
Bowman
capsule
pm
Tubular
lumen
surface Epithelium
area surface area
Thickness of
the tubular
epithelium
pm
Mean
number
of nuclei
per
tubule
sectionspm2 x iOI.un2 x iO
Sham-op
2K-ic
2K-ic
2K-ic
Untreated
Untreated
Enalapril
Ro 40-5967
9.59 0.24
9.75 0.27
9.90 0.26
11.24 025abc
7.11 0.23 5.08 0.18
6.98 0.23 5.03 0.17
7.i5 0.25 4.97 0.23
7.94 025abc 5.54 0.2tC
2.48 0.12
2.77 0.13
2.73 0.13
3.31
2.51 0.12
2.36 0.14
2.29 0.14
2.62 0.19
0.23 0.02 1.25 0.03
0.38 0.05a 1.30 0.06
0.31 0.03 1.48 0.07'
0.35 0.05a 1.45 005ab
11.76 0.36
11.56 0.33
12.52 0.45
12.33 0.51
5.7 0.2
5.6 0.3
6.7 0.2'
6.0 0.4
P < 0.05 vs. sham-operatedbp < 0.05 vs. untreated
P < 0.05 vs. enalapril
afferent arterioles and small interlobular arteries with occasionally
a typical onion skin pattern. Fibrinoid necrosis was observed only
in the untreated group. Vascular lesions were almost completely
prevented by the two antihypertensive treatments: only 1 out of 15
Ro 40-5967 treated rats had vascular lesions compared to 6 out of
16 enalapril treated rats and 11 out of 16 untreated rats (x2 =
10.8, P 0.004).
Glomerular lesions were infrequent and consisted of varying
degrees of glomeruloscierosis, ranging from segmental glomeru-
loscierosis to obsolescent glomeruli. Semi-quantitative analysis
showed that glomeruloscierosis occurred most frequently in the
untreated hypertensive group, being present in 10 out of 16
untreated rats, in 5 out of 15 Ro 40-5967 rats (Fig, 5), and in 5 out
of 16 enalapril rats. No major lesions were present in these
groups. In the untreated hypertensive rats, glomeruloscierosis was
associated with tubulointerstitial lesions, characterized by inflam-
mation, fibrosis, tubular atrophy and casts (Fig. 5). These lesions
were decreased by both treatments. The same prevalence of
lesions was observed in the second study as in the first study (data
not shown).
Quantitative morphology
Clipped kidney. Renal artery stenosis decreased cortical surface
area by 25% (P = 0.043) and medullary surface area by 29% (P =
0.041; Table 4). This change was exacerbated by both antihyper-
tensive treatments, especially in the medullary region.
Unclipped kidney. In untreated and enalapril rats, no change in
cortical or medullary surface areas was observed. In contrast, Ro
40-5967 increased both cortical and medullary surface areas.
Glomerular dimensions were not changed in untreated and
enalapril-treated rats. Ro 40-5967 increased total glomerular,
glomerular tuft and extracellular matrix surface areas to the same
extent. The peripheral urinary surface area was also increased by
Ro 40-5967, while the thickness of the Bowman's capsule was
unchanged. Hypertensive rats had an increased tubular lumen
surface area which was not changed by either treatment. Ro
40-5967 and enalapril significantly increased epithelial surface
area, but not epithelial thickness. The mean number of nuclei per
tubule section was slightly increased in enalapril rats compared to
sham-operated and untreated rats.
Discussion
The present results strongly suggest that the decrease of renal
perfusion pressure and not the blockade of the renin angiotensin
system is responsible for the worsening of the lesions of the
clipped kidney in 2K-ic rats by ACE inhibition. Interestingly,
despite a similar blood pressure decrease, Ro 40-5967 and enala-
pril had different effects on the unclipped kidney.
The medical treatment of renovascular hypertension in patients
with atherosclerotic or fibromuscular renal artery stenosis was
disappointing until the development of ACE inhibitors, which
were shown to control blood pressure in over 80% of treated
patients [211. Unfortunately, this beneficial blood pressure could
be associated with a deterioration of the functions of the stenotic
kidney [1, 2], and even renal failure when both kidneys or a
solitary kidney were involved [22—24]. It is thought that long-term
treatment of unilateral renal artery stenosis by ACE inhibition
may achieve blood pressure control by inducing pharmacological
nephrectomy [25]. Therefore, the relative advantages and disad-
vantages of the pharmacological treatment, which may reduce
renal function, or percutaneous angioplasty with its failure rate
should be considered when treating this form of high blood
pressure [26, 27].
Experimentally, in 2K-iC rats, ACE inhibition is extremely
effective in controlling high blood pressure. However, ACE
inhibition worsens renal damage of the clipped kidney, as shown
by a reduction of kidney weight and the presence of glomerular,
tubular and interstitial lesions, including whole kidney infarction
and total loss of function [4]. Two main mechanisms could
contribute to this worsening: either a major drop of renal perfu-
sion pressure downstream or the renal artery stenosis caused by
the fall in arterial pressure, or to a decrease of Ang II formation
caused by intrarenal ACE inhibition. Ang II proportionally con-
stricts efferent renal arterioles, and thus inhibition of its formation
could have led to a drop of glomerular filtration rate [6].
Until now it was not possible to evaluate the relative contribu-
tion of these two mechanisms since no drug regimen was as
effective in reducing high blood pressure as ACE inhibition.
Treatments with minoxidil [5], nitrendipine [28] and even triple
therapy [29] were unable to control high blood pressure in 2K-iC
rats. Hydralazine could be effective but only when associated with
a severe sodium restriction [30], which might have altered the
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renin-angiotensin system. This lack of blood pressure control
might have explained why these drugs did not worsen the damage
in the clipped kidney to the same extent as ACE inhibitors.
Ro 40-5967 is a new non-dihydropyridine calcium antagonist
with a long duration of action [141. A dose of 30 mg/kg, Ro
40-5967 could reduce arterial pressure to the same extent as
enalapril as shown by telemetric measurements and by the systolic
blood pressure measurements obtained with the indirect method.
In addition, the decrease of arterial pressure with Ro 40-5967 was
not associated with a blockade of the renin-angiotensin system as
shown by plasma and renal renin measurements. The blockade of
the RAS by enalapril was demonstrated by the existence of a
reactive rise in renin release and synthesis in both clipped and
unclipped kidneys, due to the inhibition of Ang II production by
ACE inhibition [31].
Despite the absence of inhibition of the RAS, Ro 40-5967
worsened the lesions of the clipped kidney (as shown by the
infarction and tubulointerstitial scores) to the same extent as
enalapril. This strongly suggests that the fall of perfusion pressure
is the main factor responsible for the renal lesions in the clipped
kidney, even in the absence of intrarenal blockade of Aug II
generation. Since a similar blood pressure decrease with a calcium
antagonist had no such effect, this result strongly does not exclude
an important role of the intrarenal renin-angiotensin system in
normal conditions. However, when renal perfusion pressure is
markedly decreased as as it is downstream of renal artery stenosis,
the local paracrine regulatory systems might become much less
important than perfusion pressure.
In contrast with the clipped kidney where both drugs seemed to
have a similar effect, the changes induced by Ro 40-5967 and
enalapril in the unclipped kidney were different, especially at the
glomerular level. Only Ro 40-5967 increased the weight of the
unclipped kidney with a proportional increase of the size of all
quantified glomerular volumes (glomerular tuft, extra cellular
matrix, peripheral urinary surface area). In contrast with a study
using nitrendipine [28], there was no dramatic increase of glomer-
ulosclerosis and of albuminuria. There was also no increase of the
thickness of the Bowman's capsule. Since Ro 40-5967, in contrast
with nitrendipine, controlled blood pressure well in the 2K-iC
rats, we might make the hypothesis that the increase of glomer-
ulosclerosis induced by nitrendipine was due to the combination
of an opening of the afferent arteries with a persistent elevated
renal perfusion pressure. A similar problem might have occurred
in a study evaluating the effect of verapamil in rats with a remnant
kidney [32]. In contrast, Ro 40-5967 might have dilated the
afferent arterioles and increased glomerular filtration rate but in
addition, reduced arterial pressure. Similar results have been
described in uninephrectomized spontaneously hypertensive rats
treated with nifedipine [33]. The fall in plasma urea and creatinine
levels constitute indirect arguments in favor of an increased
filtration rate.
ACE inhibition was able to decrease proteinuria. This result
strongly suggests that this effect is due to the intrarenal conse-
quences of the inhibition of the renin-angiotensin system. This
proteinuria present in the three groups of 2K-iC rats was due to
the non-clipped kidney since it was still present after nephrectomy
of the clipped kidney. Interestingly, Ro 40-5967 also increased the
tubular surface without producing a dilation of the tubules
(unchanged thickness of the tubular epithelium). Enalapril, but
not Ro 40-5967 increased the mean number of nuclei per tubule
sections, which would indicate a hyperplasia at this level. We have
no real explanation for this finding which might be related to a
local change of the renin-angiotensin system in tubules which are
rich in Ang II receptors [34]. Finally, both treatments were also
extremely effective in preventing vascular lesions present in this
unclipped kidney, suggesting that these lesions are a direct
consequence of the high blood pressure.
Extrapolation of the present results to the clinical situation
should be made with caution. The nature of the human disease
(atherosclerosis or fibromuscular disease) and its progressive
evolution differ from the abrupt consequences of clipping a
normal renal rat artery. Despite this, our data suggest that a
therapy decreasing arterial pressure to the same extent as ACE
inhibition in patients with renal artery stenosis will most likely also
worsen the lesions of the stenosed kidney. However, a drug such
as Ro 40-5967 might have different effects on the non-stenosed
kidney than an ACE inhibitor. This has to be taken into consid-
eration for future therapeutic investigations in these patients.
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